Cerity Partners’s AbbVie ABBV Stock Holding History

Cerity Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Hold	8,200	–	–	﹤0.01%	1575
2026 Q1	$1.78M	Buy	+8,200	New	+$1.82M	﹤0.01%	1554

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cerity Partners's ABBV Position: Q2 2026 in Review

Cerity Partners increased its AbbVie (ABBV) stake by 4.9% in Q2 2026, buying an estimated $12.9M and bringing the position to 1,275,203 shares worth $321M. The position accounts for 0.39% of the portfolio, ranked #44.

Cerity Partners first reported a position in ABBV in Q1 2017 and has held it in 38 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cerity Partners held 1,275,203 shares of AbbVie worth $321M as of Q2 2026.
Cerity Partners bought 59,781 AbbVie shares in Q2 2026, an estimated $12.9M.
AbbVie made up 0.39% of Cerity Partners's portfolio in Q2 2026, its #44 holding.
Cerity Partners first reported a position in AbbVie in Q1 2017 and has held it in 38 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.